OncoGenex Pharmaceuticals (OGXI)
OncoGenex Pharmaceuticals Revenues: 1.316M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OGXI Revenues Rankings
| Overall | 3rd percentile | 4299 of 4432 |
| Sector | 14th percentile | 404 of 470 in Healthcare |
| Industry | 23rd percentile | 101 of 132 in Biotechnology |
OGXI Revenues Range, Past 5 Years
| Minimum | 1.174M | Sep 2011 |
| Maximum | 4.881M | Sep 2010 |
| Average | 2.370M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these OGXI related companies
OGXI News
Listen to $OGXI Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3ezb
about 27 days ago by earningscast
about 27 days ago by earningscast
2012 Economic Outlook - Report Highlights OncoGenex Pharmaceuticals Inc and Pacira Pharmaceuticals Inc
Apr 26, 9:00AM Marketwire
Apr 26, 9:00AM Marketwire
Listen to $OGXI Oncogenex Pharmaceuticals, Inc. at BioCentury & Thomson Reuters - live at 10:30 AM, ondemand after - http://stks.co/3R2P
about 40 days ago by earningscast
about 40 days ago by earningscast
$OGXI forms bearish "Descending Continuation Triangle" chart pattern. http://stks.co/3LXH
about 47 days ago by RecogniaEvents
about 47 days ago by RecogniaEvents
FMR LLC Raises Stake in OncoGenex Pharmaceuticals, Inc. (OGXI) to 10.32%
Apr 10, 9:16AM Street Insider
Apr 10, 9:16AM Street Insider
Leerink Swann Starts OncoGenex Pharmaceuticals (OGXI) at Outperform; Evolution of Drug Development
Mar 27, 7:02AM Street Insider
Mar 27, 7:02AM Street Insider
RT @danshep55 $OGXI 13.14 break/ why all of a sudden such a love for reverse candle patterns?
about 67 days ago by ivan_bg
about 67 days ago by ivan_bg
OncoGenex Pharmaceuticals Announces Full Exercise of Overallotment Option by Underwriters
Mar 23, 9:01AM Benzinga
Mar 23, 9:01AM Benzinga
OncoGenex Pharmaceuticals, Inc. Announces Full Exercise of Overallotment Option by Underwriters
Mar 23, 9:00AM PR Newswire
Mar 23, 9:00AM PR Newswire
$OGXI is -5.5% down since open on unusual high volume and -5.2% down since close.
about 71 days ago by TradeBot
about 71 days ago by TradeBot
$OGXI 200 Day SMA Cross - Price crossed below 200 day SMA (13.0118). Confirmed by volume.
about 71 days ago by TradeIdeasQuant
about 71 days ago by TradeIdeasQuant
$OGXI 200 Day SMA Cross - Price crossed above 200 day SMA (13.0118). Confirmed by volume.
about 71 days ago by TradeIdeasQuant
about 71 days ago by TradeIdeasQuant
OncoGenex Pharmaceuticals Announces Proposed Public Offering of Common Stock
Mar 15, 4:01PM Benzinga
Mar 15, 4:01PM Benzinga
Listen to $OGXI Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2kCh
about 83 days ago by earningscast
about 83 days ago by earningscast
Edison Expands Oncology Sector Presence with Launch of Research Coverage on OncoGenex Pharmaceuticals
Nov 07, 9:05AM Business Wire
Nov 07, 9:05AM Business Wire
Notes from $OGXI 2q2011 call: http://goo.gl/AW90x Delays for 2 of 3 phase 3 trials of custersen for prostate/lung cancer w/ $TEVA $ISIS
about 276 days ago by BioDueDiligence
about 276 days ago by BioDueDiligence
Quick notes from $TEVA 2q11 CC re $MNTA $NVS and partners $AIS $BPAX $ISIS $OGXI: http://goo.gl/q8RzV
about 287 days ago by BioDueDiligence
about 287 days ago by BioDueDiligence
$ogxi nothing odd in the print last night. just illiquid is my guess.
about 299 days ago by Leadfoot88
about 299 days ago by Leadfoot88
@adamfeuerstein Love the chat. If $OGXI $TEVA $ISIS can get an SPA for pain palliation endpoint, why can't $EXEL get a non-survival one too?
about 348 days ago by BioDueDiligence
about 348 days ago by BioDueDiligence
NEW POST: "The Situation Sometimes Rewards Grenades" http://bit.ly/m13S8D $ALXA $DYAX $IBB $IWM $OGXI $ONTY $QCOR $SPY
about 353 days ago by chessNwine
about 353 days ago by chessNwine
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OGXI | 12.77 | -0.32 | -2.44% | 127.63M |
| OGE | 52.80 | -0.63 | -1.18% | 5.240B |
| OFLX | 11.81 | +0.10 | +0.85% | 118.15M |
| OFI | 4.390 | -0.04 | -0.91% | 69.45M |
| OFG | 10.51 | -0.27 | -2.50% | 440.90M |
| OFC | 21.93 | -0.75 | -3.31% | 1.633B |
| OESX | 2.14 | +0.07 | +3.38% | 47.63M |
| NXZ | 15.19 | -0.04 | -0.26% | |
| NXY | 15.75 | -0.59 | -3.61% | 8.634B |
| NXTM | 15.29 | -0.17 | -1.10% | 861.74M |